Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-7: Inclisiran PK in Renal Impairment
NCT03159416Phase 1Completed
- Sponsor
- The Medicines Company
- Start
- Jun 2017
- Primary completion
- Mar 2018
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of inclisiran in hypercholesterolemia (4 arms), sponsored by The Medicines Company. Primary endpoints: Maximum Observed Plasma Concentration at Day 30, Time to Maximum Concentration at Day 30 and 5 more. Started Jun 2017; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03159416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159416.